Sodium Benzoate
Phase 2Small molecule
Sodium benzoate is used to treat a rare genetic condition called urea cycle disorder, where the body cannot properly break down ammonia, which can damage the brain. It helps the body remove excess ammonia by providing an alternative pathway for ammonia elimination.[1] Sodium Benzoate is currently being investigated across 6 indications[3], with its most advanced program in Phase 2.[1]
Sodium Benzoate is one of 46 small molecule programs targeting Combined D,L-2-hydroxyglutaric Aciduria. It is currently in Phase 2.
6
Indications
29
Total Trials
3
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in AIN
#DrugCompanyPhaseTrials
1Jevtana
SanofiPhase 2
Lynparza
AstraZenecaPhase 2
Reblozyl
Bristol-Myers SquibbPhase 2
Avastin
RochePhase 2
Plaquenil
Jazz PharmaceuticalsPhase 2
GM-CSF
YY-mAbs Therapeutics
Phase 3
Paraplatin
AAvyxa
Phase 2
Viracept
AAgouron Pharmaceuticals
Phase 2
Brukinsa
BBeOne Medicines
Phase 2
Ayvakit
BBlueprint Medicines
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spinal Muscular Atrophy3 trials
Psychosis1 trial
Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.
Withdrawn·—·Phase 2·NCT02026947
Schizophrenia1 trial
Hyperammonemia1 trial
Urea Cycle Disorders1 trial
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
Completed·—·N/A·NCT02111200·7 enrolled
21 more indications
Acute Myeloid Leukemia1 trial
Hematologic Cancer1 trial
Myelodysplastic Syndrome1 trial
Colorectal Cancer1 trial
Huntington's Disease1 trial
Relapsed or Refractory1 trial
Insulin Secretion1 trial
Non-Small Cell Lung Cancer1 trial
Argininosuccinic Aciduria1 trial
Dietary Intervention1 trial
Amyotrophic Lateral Sclerosis1 trial
Medium Chain Acyl-Coa Dehydrogenase Deficiency1 trial
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Recruiting·—·Phase 2·NCT06773026·24 enrolled
Unspecified2 trials
An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)
Enrolling by invitation·—·Phase 1·NCT07125066·1 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium Benzoate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- LLiminal BioSciences Ltd.